APO Research
Talk to an analyst

APO RESEARCH · REPORT

Angina Pectoris Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Angina Pectoris Drugs Market Outlook and Growth Opportunities 2026

20 December 2025193 pages

Choose your research edition.

Industry ResearchAngina Pectoris Drugs Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Angina Pectoris Drugs Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Angina Pectoris Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angina Pectoris Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Angina Pectoris Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Angina Pectoris Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Angina Pectoris Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Angina Pectoris Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Angina Pectoris Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Angina Pectoris Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Angina Pectoris Drugs market include Teva Pharmaceutical, Novartis, Merck, Mylan, Pfizer, GlaxoSmithKline, Bayer, AstraZeneca and Gilead, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Angina Pectoris Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Angina Pectoris Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Angina Pectoris Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Angina Pectoris Drugs market.

Angina Pectoris Drugs Segment by Company

Teva Pharmaceutical

Novartis

Merck

Mylan

Pfizer

GlaxoSmithKline

Bayer

AstraZeneca

Gilead

Angina Pectoris Drugs Segment by Type

Beta Blockers

Calcium Antagonists

Anticoagulants

Anti-Platelets

Others

Angina Pectoris Drugs Segment by Application

Clinics

Hospitals

ASCs

Angina Pectoris Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Angina Pectoris Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Angina Pectoris Drugs key companies, revenue, market share, and recent developments.

3. To split the Angina Pectoris Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Angina Pectoris Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Angina Pectoris Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Angina Pectoris Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angina Pectoris Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angina Pectoris Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angina Pectoris Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Angina Pectoris Drugs industry.

Chapter 3: Detailed analysis of Angina Pectoris Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Angina Pectoris Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Angina Pectoris Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Angina Pectoris Drugs Industry Trends Table 2. Angina Pectoris Drugs Industry Drivers Table 3. Angina Pectoris Drugs Industry Opportunities and Challenges Table 4. Angina Pectoris Drugs Industry Restraints Table 5. Global Angina Pectoris Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Angina Pectoris Drugs Revenue Share by Company (2021-2026) Table 7. Global Angina Pectoris Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Angina Pectoris Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Angina Pectoris Drugs Company, Product Type & Application Table 10. Global Angina Pectoris Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Angina Pectoris Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Beta Blockers Table 15. Significant Companies of Calcium Antagonists Table 16. Significant Companies of Anticoagulants Table 17. Significant Companies of Anti-Platelets Table 18. Significant Companies of Others Table 19. Global Angina Pectoris Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Angina Pectoris Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Angina Pectoris Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Angina Pectoris Drugs Sales Value Share by Type (2021-2026) Table 23. Global Angina Pectoris Drugs Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Clinics Table 25. Significant Companies of Hospitals Table 26. Significant Companies of ASCs Table 27. Global Angina Pectoris Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Angina Pectoris Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Angina Pectoris Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Angina Pectoris Drugs Sales Value Share by Application (2021-2026) Table 31. Global Angina Pectoris Drugs Sales Value Share by Application (2027-2032) Table 32. Global Angina Pectoris Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Angina Pectoris Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Angina Pectoris Drugs Sales Value Share by Region (2021-2026) Table 35. Global Angina Pectoris Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Angina Pectoris Drugs Sales Value Share by Region (2027-2032) Table 37. Global Angina Pectoris Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Angina Pectoris Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Angina Pectoris Drugs Sales Value Market Share by Country (2021-2026) Table 40. Global Angina Pectoris Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Angina Pectoris Drugs Sales Value Market Share by Country (2027-2032) Table 42. Teva Pharmaceutical Company Information Table 43. Teva Pharmaceutical Business Overview Table 44. Teva Pharmaceutical Angina Pectoris Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Teva Pharmaceutical Angina Pectoris Drugs Product Portfolio Table 46. Teva Pharmaceutical Recent Development Table 47. Novartis Company Information Table 48. Novartis Business Overview Table 49. Novartis Angina Pectoris Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Novartis Angina Pectoris Drugs Product Portfolio Table 51. Novartis Recent Development Table 52. Merck Company Information Table 53. Merck Business Overview Table 54. Merck Angina Pectoris Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Merck Angina Pectoris Drugs Product Portfolio Table 56. Merck Recent Development Table 57. Mylan Company Information Table 58. Mylan Business Overview Table 59. Mylan Angina Pectoris Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Mylan Angina Pectoris Drugs Product Portfolio Table 61. Mylan Recent Development Table 62. Pfizer Company Information Table 63. Pfizer Business Overview Table 64. Pfizer Angina Pectoris Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Pfizer Angina Pectoris Drugs Product Portfolio Table 66. Pfizer Recent Development Table 67. GlaxoSmithKline Company Information Table 68. GlaxoSmithKline Business Overview Table 69. GlaxoSmithKline Angina Pectoris Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. GlaxoSmithKline Angina Pectoris Drugs Product Portfolio Table 71. GlaxoSmithKline Recent Development Table 72. Bayer Company Information Table 73. Bayer Business Overview Table 74. Bayer Angina Pectoris Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Bayer Angina Pectoris Drugs Product Portfolio Table 76. Bayer Recent Development Table 77. AstraZeneca Company Information Table 78. AstraZeneca Business Overview Table 79. AstraZeneca Angina Pectoris Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. AstraZeneca Angina Pectoris Drugs Product Portfolio Table 81. AstraZeneca Recent Development Table 82. Gilead Company Information Table 83. Gilead Business Overview Table 84. Gilead Angina Pectoris Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Gilead Angina Pectoris Drugs Product Portfolio Table 86. Gilead Recent Development Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Angina Pectoris Drugs Product Image Figure 2. Global Angina Pectoris Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Angina Pectoris Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Angina Pectoris Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Beta Blockers Image Figure 8. Calcium Antagonists Image Figure 9. Anticoagulants Image Figure 10. Anti-Platelets Image Figure 11. Others Image Figure 12. Global Angina Pectoris Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Angina Pectoris Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Angina Pectoris Drugs Sales Value Share by Type (2021-2032) Figure 15. Clinics Image Figure 16. Hospitals Image Figure 17. ASCs Image Figure 18. Global Angina Pectoris Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Angina Pectoris Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Angina Pectoris Drugs Sales Value Share by Application (2021-2032) Figure 21. Global Angina Pectoris Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Angina Pectoris Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Angina Pectoris Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. North America Angina Pectoris Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Angina Pectoris Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Angina Pectoris Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Angina Pectoris Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Angina Pectoris Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Angina Pectoris Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. South America Angina Pectoris Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Angina Pectoris Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Angina Pectoris Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Angina Pectoris Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Beta Blockers
  • Calcium Antagonists
  • Anticoagulants
  • Anti-Platelets
  • Others
Applications
  • Clinics
  • Hospitals
  • ASCs
Companies covered
  • Teva Pharmaceutical
  • Novartis
  • Merck
  • Mylan
  • Pfizer
  • GlaxoSmithKline
  • Bayer
  • AstraZeneca
  • Gilead

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Angina Pectoris Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Angina Pectoris Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Angina Pectoris Drugs Market Dynamics
  1. 2.1 Angina Pectoris Drugs Industry Trends
  2. 2.2 Angina Pectoris Drugs Industry Drivers
  3. 2.3 Angina Pectoris Drugs Industry Opportunities and Challenges
  4. 2.4 Angina Pectoris Drugs Industry Restraints
3 Angina Pectoris Drugs Market by Company
  1. 3.1 Global Angina Pectoris Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Angina Pectoris Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Angina Pectoris Drugs Company Ranking (2024-2026)
  4. 3.4 Global Angina Pectoris Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Angina Pectoris Drugs Company Product Type and Application
  6. 3.6 Global Angina Pectoris Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Angina Pectoris Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Angina Pectoris Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Angina Pectoris Drugs Market by Type
  1. 4.1 Angina Pectoris Drugs Type Introduction
  2. 4.1.1 Beta Blockers
  3. 4.1.2 Calcium Antagonists
  4. 4.1.3 Anticoagulants
  5. 4.1.4 Anti-Platelets
  6. 4.1.5 Others
  7. 4.2 Global Angina Pectoris Drugs Sales Value by Type
  8. 4.2.1 Global Angina Pectoris Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Angina Pectoris Drugs Sales Value by Type (2021-2032)
  10. 4.2.3 Global Angina Pectoris Drugs Sales Value Share by Type (2021-2032)
5 Angina Pectoris Drugs Market by Application
  1. 5.1 Angina Pectoris Drugs Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 ASCs
  5. 5.2 Global Angina Pectoris Drugs Sales Value by Application
  6. 5.2.1 Global Angina Pectoris Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Angina Pectoris Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Angina Pectoris Drugs Sales Value Share by Application (2021-2032)
6 Angina Pectoris Drugs Regional Value Analysis
  1. 6.1 Global Angina Pectoris Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Angina Pectoris Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Angina Pectoris Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Angina Pectoris Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Angina Pectoris Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Angina Pectoris Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Angina Pectoris Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Angina Pectoris Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Angina Pectoris Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Angina Pectoris Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Angina Pectoris Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Angina Pectoris Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Angina Pectoris Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Angina Pectoris Drugs Sales Value Share by Country, 2025 VS 2032
7 Angina Pectoris Drugs Country-level Value Analysis
  1. 7.1 Global Angina Pectoris Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Angina Pectoris Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Angina Pectoris Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Angina Pectoris Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Angina Pectoris Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Angina Pectoris Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Angina Pectoris Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical
  2. 8.1.1 Teva Pharmaceutical Company Information
  3. 8.1.2 Teva Pharmaceutical Business Overview
  4. 8.1.3 Teva Pharmaceutical Angina Pectoris Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Angina Pectoris Drugs Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Angina Pectoris Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Angina Pectoris Drugs Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Angina Pectoris Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Angina Pectoris Drugs Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Angina Pectoris Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Angina Pectoris Drugs Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Angina Pectoris Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Angina Pectoris Drugs Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 GlaxoSmithKline
  32. 8.6.1 GlaxoSmithKline Company Information
  33. 8.6.2 GlaxoSmithKline Business Overview
  34. 8.6.3 GlaxoSmithKline Angina Pectoris Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline Angina Pectoris Drugs Product Portfolio
  36. 8.6.5 GlaxoSmithKline Recent Developments
  37. 8.7 Bayer
  38. 8.7.1 Bayer Company Information
  39. 8.7.2 Bayer Business Overview
  40. 8.7.3 Bayer Angina Pectoris Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bayer Angina Pectoris Drugs Product Portfolio
  42. 8.7.5 Bayer Recent Developments
  43. 8.8 AstraZeneca
  44. 8.8.1 AstraZeneca Company Information
  45. 8.8.2 AstraZeneca Business Overview
  46. 8.8.3 AstraZeneca Angina Pectoris Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AstraZeneca Angina Pectoris Drugs Product Portfolio
  48. 8.8.5 AstraZeneca Recent Developments
  49. 8.9 Gilead
  50. 8.9.1 Gilead Company Information
  51. 8.9.2 Gilead Business Overview
  52. 8.9.3 Gilead Angina Pectoris Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Gilead Angina Pectoris Drugs Product Portfolio
  54. 8.9.5 Gilead Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst